- Chime Biologics enters strategic collaboration with South Korea’s MedPacto.
- The agreement will advance cancer therapeutics through clinical manufacturing support.
Chime Biologics, a global CDMO, has announced a new partnership with MedPacto, a KOSDAQ-listed South Korean company focused on developing cancer therapeutics. This strategic collaboration aims to streamline Chemistry, Manufacturing, and Controls (CMC) process development for MedPacto’s preclinical drug candidates, with a focus on expediting Investigational New Drug (IND) submissions.
MedPacto will benefit from Biologics’ expertise in biologics development, leveraging the CDMO’s capabilities from tech transfer to cGMP clinical manufacturing. The collaboration aligns with Biologics’ expansion efforts in South Korea, where it aims to solidify its role in biopharmaceutical development through partnerships in antibody drug and biosimilar production.
Dr. Jungwon Woo, President of MedPacto, expressed confidence in the collaboration, saying, “We are highly impressed by Chime Biologics’ development and manufacture expertise, which is crucial helping us expand into major global markets. Their ability to meet international standards will greatly support our efforts to advance our assets into a new stage.”
Biologics’ expansion plan includes increasing its manufacturing capacity to 100,000 liters, a move intended to strengthen its market position in South Korea and globally. Dr. Jimmy Wei, President of Biologics, highlighted the significance of this partnership, stating, “This partnership marks the beginning of a long-term relationship aimed at advancing pharmaceutical innovation. It aligns with our growth strategy in South Korea and aligns with our commitment to the region’s biopharmaceutical landscape.”